# Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

> **NCT03117049** · PHASE3 · COMPLETED · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 550 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** ONO-4538
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Bevacizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03117049
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-13
- **Primary completion:** 2020-02-10
- **Final completion:** 2023-12-04
- **Target enrollment:** 550 (ACTUAL)
- **Last updated:** 2024-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03117049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03117049, "Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03117049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*